UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 8.01 | Other Events. |
On June 28, 2022, 89bio, Inc. (the “Company”) issued a press release announcing positive initial data from its Phase 2 trial (ENTRIGUE) of pegozafermin (previously BIO89-100) in patients with severe hypertriglyceridemia (SHTG). The Company will host a conference call today, Tuesday, June 28, 2022 at 4:30 pm, Eastern Time, to discuss the data results.
A copy of the press release and the presentation which will be referenced during the conference call are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits.
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated June 28, 2022 | |
| 99.2 | Slide Presentation, dated June 28, 2022 | |
| 104 | The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| 89bio, Inc. | ||||||
| Date: June 28, 2022 | By: | /s/ Rohan Palekar | ||||
| Rohan Palekar | ||||||
| Chief Executive Officer | ||||||
Exhibit 99.1
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy -
- Observed significant and potent reductions in atherogenic lipids (non-HDL-C and apo B), liver fat, and improvements in liver enzymes and glycemic control markers -
- ENTRIGUE results support 89bio’s transition to a late-stage development company; Phase 3 expected to
initiate in first half of 2023 -
- Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST -
SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) - 89bio, Inc. (Nasdaq: ETNB), today announced positive topline results from ENTRIGUE, the Phase 2 proof-of-concept study evaluating pegozafermin for the treatment of severe hypertriglyceridemia (SHTG). Treatment with pegozafermin resulted in clinically meaningful and significant reductions in triglycerides (TG) from baseline across all doses (with a 63% reduction in the highest dosing group; p<0.001) and various subgroups, statistically significant improvements in key markers of cardiovascular risk (non-HDL-C and apo B), reductions in liver fat, and improvements in glycemic control markers.
“There is a critical need for SHTG treatment options that not only reduce triglycerides but also address broader cardiometabolic risks including hepatic steatosis and improve insulin sensitivity” said Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart & Vascular Center, Professor of Medicine, Harvard Medical School. “Treatment with pegozafermin demonstrated impressive triglyceride reduction coupled with meaningful reductions in non-HDL-C and improvements in cardiometabolic parameters. Taken together, pegozafermin’s profile in ENTRIGUE shows great potential to uniquely address the key needs for patients with SHTG.”
Results showed statistically significant reductions in median TGs from baseline across all dose groups treated with pegozafermin, compared to placebo after 8 weeks. Additionally, results were consistent in patients not on background therapy or on background therapy (consistent results on statins or statin combos, prescription fish oils, and fibrates) and across various subgroups, including those with the greatest disease burden, such as Type 2 diabetes and baseline TG levels ≥750 mg/dL.
Median Percent Change in Triglycerides from Baseline at Week 8
| Dosing group |
Median TG reduction |
|||
| Placebo (n=18) |
-12 | % | ||
| 9mg QW (n=16) |
-57 | %*** | ||
| 18mg QW (n=17) |
-56 | %*** | ||
| 27mg QW (n=18) |
-63 | %*** | ||
| 36mg Q2W (n=16) |
-36 | %* | ||
| * | p<0.05; *** p<0.001 versus placebo based on Wilcoxon Rank-Sum Test |
Median Percent Change in Triglycerides from Baseline at Week 8
| Dosing group |
Patients on background therapy1 |
Patients not on background therapy |
||||||
| Placebo |
-18 | % | 5 | % | ||||
| 9mg QW |
-59 | % | -50 | % | ||||
| 18mg QW |
-56 | % | -59 | % | ||||
| 27mg QW |
-68 | % | -62 | % | ||||
| 36mg Q2W |
-45 | % | -21 | % | ||||
| 1. | Background therapy defined as concomitant lipid modifying therapy |
Patients on background therapy: placebo (n=11), 9mg QW (n=8), 18mg QW (n=9), 27mg QW (n=10), 36mg Q2W (n=8)
Patients not on background therapy: placebo (n=6), 9mg QW (n=8), 18mg QW (n=8), 27mg QW (n=6), 36mg Q2W (n=8)
Responder analysis on primary endpoint of TG reduction demonstrated:
| • | A significantly higher proportion of patients reached the initial treatment goal of reducing TG <500 mg/dL on pooled pegozafermin vs. placebo (80% vs. 29%; p<0.001). |
| • | Treatment with 27mg QW resulted in a significantly higher proportion of patients achieving TG normalization (<150 mg/dL) vs. placebo (31% vs. 0%; p<0.05) and |
| • | Greater proportion of patients achieved significant TG reduction of ≥ 50% from baseline vs. placebo (75% vs. 6%; p<0.001). |
Pegozafermin treatment also resulted in significant improvements compared to placebo (mean percent change from baseline) and clinically meaningful changes on an absolute basis in non-HDL-C and apo B that are key markers of cardiovascular risk (absolute change from baseline of 55 mg/dL and 22 mg/dL in non-HDL-C and apo B respectively with 27mg QW dose). Patients treated across all doses with pegozafermin also demonstrated an improvement in HDL-C and no change in LDL-C vs. placebo.
Mean Percent Change in non-HDL-C and apo B from Baseline at Week 8
| Dosing group |
non-HDL-C | apo B | ||||||
| Placebo |
-3 | % | -1 | % | ||||
| 9mg QW |
-14 | % | -11 | % | ||||
| 18mg QW |
-22 | %** | -14 | %* | ||||
| 27mg QW |
-29 | %*** | -18 | %** | ||||
| 36mg Q2W |
-9 | % | -1 | % | ||||
| * | p<0.05; ** p<0.01; *** p<0.001 versus placebo based on MMRM analysis |
Pegozafermin treatment resulted in a mean relative reduction in liver fat from baseline at week 8 across all dose groups versus placebo in the substudy of patients with magnetic resonance imaging – proton density fat factor (MRI-PDFF) and the results are summarized in the table below.
Mean Relative Reduction in Liver Fat vs. Baseline at Week 8 in Substudy
| Dosing group |
MRI-PDFF | |||
| Placebo (n=6) |
-5 | % | ||
| 9mg QW (n=3) |
-55 | %* | ||
| 18mg QW (n=5) |
-38 | % | ||
| 27mg QW (n=7) |
-44 | % | ||
| 36mg Q2W (n=2) |
-37 | % | ||
| * | p<0.05 versus placebo based on ANCOVA analysis |
| • | A significant proportion of patients responded to therapy with up to 88% and 41% of treated patients vs. 0% of placebo patients achieving a ≥30% or a ≥50% reduction in liver fat versus baseline, respectively. |
| • | Results also demonstrated a significant reduction in liver enzymes and an improvement in glycemic control markers in pegozafermin treated patients. |
Pegozafermin continues to be generally well tolerated with a favorable safety profile across doses consistent with prior studies. In ENTRIGUE, the most commonly reported treatment-related adverse events were nausea, diarrhea, and injection site reactions, all which were classified as mild or moderate. No tremors or transaminase elevation adverse events were observed. There were no drug-related serious adverse events and two Grade 2 treatment-related discontinuations.
ENTRIGUE is a randomized, double-blind, placebo-controlled trial that enrolled a total of 85 SHTG patients either on stable background therapy (55% - statin/statin combos, and/or prescription fish oil, and/or fibrates) or not on any background therapy treated weekly or every two-weeks with pegozafermin. The trial enrolled an advanced population with high risk of cardiovascular disease as evidenced by mean baseline values of treated patients with TGs of 733 mg/dL, non-HDL-C of 211 mg/dL, 43.5% with HbA1c ≥6.5%, and liver fat content of 20.1%.
Hank Mansbach, Chief Medical Officer of 89bio, commented, “We are extremely pleased by the robust and consistent results observed across multiple measures and patient subgroups in this study. These results add to the body of evidence demonstrating pegozafermin’s unique and differentiated profile based on broad metabolic effects and a favorable safety/tolerability profile. These positive data support the advancement into a Phase 3 trial in SHTG based on regulatory precedent, which we plan to initiate in the first half of 2023. These results also build confidence in our ongoing Phase 2b ENLIVEN trial in NASH with data expected in the first quarter of 2023.”
Rohan Palekar, Chief Executive Officer of 89bio, added, “SHTG remains a significant market opportunity with a large patient population who are underserved with the existing therapeutic options. In market research, physicians have indicated a strong preference for a drug that could address the metabolic co-morbidities, especially the liver fat benefit seen in a majority of these patients. We believe the results from ENTRIGUE position pegozafermin as potentially the first FGF21 analog to market and to become an important metabolic drug for treatment of cardio-metabolic and liver disease.”
Today’s Conference Call Information
89bio will host a conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST today, June 28, 2022. Analysts and investors can participate in the conference call by dialing (1-877-704-4453) or domestic callers and +1 (1-201-389-0920) for international callers, using the conference ID 13730718. The webcast can be accessed live here and on the Events & Presentations page in the Investors section of the 89bio website, www.89bio.com. The webcast will be archived on the company’s website for at least 30 days after the conference call.
About pegozafermin
Pegozafermin is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). FGF21 is an endogenous hormone that modulates important drivers of NASH including glycemic control, steatosis, inflammation and fibrosis. Pegozafermin was specifically engineered using a unique glycoPEGylated technology to extend the half-life while maintaining potency. Recent Phase 1b/2a data with pegozafermin in biopsy-confirmed NASH patients demonstrated clinically meaningful changes on histology endpoints and non-invasive measures of total liver health, in patients with NASH as well as many of the underlying metabolic comorbidities commonly associated with NASH. Pegozafermin is currently being evaluated in the Phase 2b ENLIVEN trial in NASH.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.
Forward-looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, the therapeutic potential and clinical benefits of pegozafermin for the treatment of SHTG, the efficacy and safety of pegozafermin, pegozafermin’s potential as a compelling treatment option for SHTG, the expected timing of the initiation of the Phase 3 trial in SHTG, the expected timing of data from the ongoing Phase 2b ENLIVEN trial in NASH and the relationship between the results from the positive data from Phase 2 ENTRIGUE trial and results of future or ongoing clinical studies, including the ongoing Phase 2b ENLIVEN trial in NASH. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While 89bio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in 89bio’s filings with the SEC), many of which are beyond 89bio’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; and other risks and uncertainties identified in 89bio’s Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and other subsequent disclosure documents filed with the SEC. 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Nasdaq: ETNB Powerful Science Meaningful Medicines Changing Lives Pegozafermin Phase 2 (ENTRIGUE) Topline Results in Severe Hypertriglyceridemia (SHTG) Exhibit 99.2
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements concerning our plans, objectives, goals, strategies, future events, plans or intentions relating to product candidates, potential market opportunities, estimates of market size, estimates of market growth, the potential clinical benefit, effect on histology and safety and tolerability profile of pegozafermin (formerly BIO89-100), the clinical potential of pegozafermin, potential indications for pegozafermin, the association of clinical data with potential clinical benefit in other indications, the anticipated timing, design, endpoints, and conduct of our ongoing clinical trials for pegozafermin, including the Phase 2 ENTRIGUE trial, the timing of anticipated milestones, the timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated product development efforts and our liquidity and capital resources. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks and uncertainties, including: expectations regarding the timing and outcome of the Phase 2b ENLIVEN trial in NASH and Phase 2 ENTRIGUE trial in SHTG; expectations regarding the timing of topline data; our ability to execute on our strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; our substantial dependence on the success of our lead product candidate; competition from competing products; the effect of the COVID-19 pandemic on our clinical trials and business operations, and the impact of general economic, health, industrial or political conditions in the United States or internationally; our reliance on third-party manufacturers and vendors to produce our product candidate and any future product candidates; the sufficiency of our capital resources and our ability to raise additional capital; and other risks and uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this presentation including those described more fully our most recent Form 10-K and Form 10-Q under the caption “Risk Factors” and elsewhere in such report and in other subsequent disclosure documents filed with the SEC. We cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. Forward-looking statements are not historical facts, and reflect our current views with respect to future events. Given the significant uncertainties, you should evaluate all forward-looking statements made in this presentation in the context of these risks and uncertainties and not place undue reliance on these forward-looking statements as predictions of future events. All forward-looking statements in this presentation apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this presentation. We disclaim any intent to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by law. We obtained the industry, market and competitive position data used throughout this presentation from our own internal estimates and research, as well as from industry and general publications, and research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of the industry and market, which we believe to be reasonable. In addition, while we believe the industry, market and competitive position data included in this presentation is reliable and based on reasonable assumptions, we have not independently verified any third-party information, and all such data involve risks and uncertainties and are subject to change based on various factors. Disclaimer
Results support advancing to Phase 3 – potential first FGF21 analog to market Potentially quicker and efficient regulatory path to approval in SHTG Phase 3 initiation expected in 1H23; topline results ~ 2 years from study start ENTRIGUE results demonstrate compelling and differentiated profile in SHTG Significant impact on triglycerides, liver fat, and associated metabolic co-morbidities Favorable safety and tolerability profile Exceeds target product profile defined by literature, KOLs & treating physicians Pegozafermin – Potential Important New Cardio-Metabolic Drug SHTG represents a large potential opportunity given pegozafermin’s profile High unmet needs for better therapeutic options to address broader metabolic comorbidities Approved therapies are sub-optimal resulting in large uncontrolled or untreated population ENTRIGUE results increase confidence in overall pegozafermin program - NASH ENLIVEN topline now expected in 1Q23
Average patient in ENTRIGUE study was estimated to have a 23% risk of Major Cardiovascular Events (MACE) over 10 years (per ACC ASCVD risk estimator) Average patient: no prior CV event, 54 years old, male, white, BP 131/81, total cholesterol 240, HDL 28, LDL 89, diabetic, non-smoker, taking anti-hypertensive medication, no statins or aspirin. Individual risks may vary. Patients with SHTG have multiple co-morbidities and significant health risks Increased Cardiovascular (CV) Risk Increased risk of CV disease, heart failure and ischemic stroke Increased mortality in patients with CHD Increased risk of Acute Pancreatitis Increased prevalence of Diabetes SHTG is a Serious Disease in Need of Better Treatment Options “Most patients with severe hypertriglyceridemia have multiple ASCVD risk factors and are at enhanced risk of developing atherosclerotic disease. This risk is conveyed by atherogenic VLDL plus other factors, such as obesity, metabolic syndrome, and hyperglycemia” [2018 AHA/ACC Guideline For Cholesterol Management] ASCVD = Atherosclerotic cardiovascular disease
High Prevalence Disease: ~4M patients in the United States SHTG is a Large Underserved Market Existing therapies have limitations Fish Oils: Minimal to moderate TG reduction, LDL elevations (some), no liver benefits Fibrates: Moderate TG reduction, major increase in LDL, myopathies Statins (not approved for SHTG): Moderate TG reduction with high intensity regimen, other lipid benefits, potential liver and muscle toxicity ~50%* of diagnosed/treated patients are uncontrolled representing ~ 750,000 to 1,000,000 patients Market needs a therapy that offers: More effective triglyceride reduction Improvement in other lipids that impact CV risk Improvement in liver fat and no worsening of liver function Improvement in glycemic control measures * 50% is based on registrational trials of Vascepa and Epanova (4mg/day) approved in SHTG
Stojsavljevic-Shapeski S et al J Clin Transl Hepatol 2021;9(1):51-59 Proposed Mechanisms of Action for Pegozafermin in SHTG Adipose tissue Decrease lipogenesis and release of FFA Improve insulin resistance Increase TG uptake Increase adiponectin Liver Increase β-oxidation Decrease de novo lipogenesis Decrease FFA / TG Muscle Increase FFA oxidation Muscle Adipocytes ↓Glucose ↑FFA oxidation INSULIN RESISTANCE ↑Adiponectin ↓Lectin ↑Lipolysis ↓TG ↓FFA Inflammation Apoptosis Fibrosis Mitochondrial dysfunction ER stress ↓FFA TG Steatosis ↑ β-oxidation ↓ Lipogenesis Liver
ENTRIGUE Data
ENTRIGUE – Phase 2 SHTG Trial Design 8 Weeks SCREENING RANDOMIZATION SAFETY FOLLOW-UP 36mg Q2W Pegozafermin (n=16) 27mg QW Pegozafermin (n=18) 18mg QW Pegozafermin (n=17) 9mg QW Pegozafermin (n=16) PLACEBO (n=18) Safety analysis set, n=85 (patients who received at least 1 dose) Full analysis set, n=82 (patients with at least 1 post-baseline TG assessment) MRI analysis set n=23 (patients with baseline and end of treatment MRIs) Magnetic Resonance Imaging – Proton Density Fat Fraction QW, once-weekly; Q2W, once every two weeks. KEY INCLUSION CRITERIA TG ≥500 mg/dL and ≤2,000 mg/dL Background therapy: statins and/or prescription fish oil and/or fibrates OR none Primary endpoint: % Change in TGs from baseline PRIMARY ENDPOINT Lipids: non-HDL-C, HDL-C, Apo-B Liver fat (MRI-PDFF) Glycemic control KEY SECONDARY ENDPOINTS
Baseline Characteristics Represents an Advanced Population at High Risk for CV Disease Parameter Mean or % Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=16) PGZ 18mg QW (n=17) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Total (n=85) Age (years) 57.5 52.7 54.6 49.2 53.9 53.1 53.7 Male (%) 66.7 77.6 68.8 82.4 72.2 87.5 75.3 Body Weight (kg) 98 99 100 97 99 99 99 Type 2 Diabetes (%) 61.1 47.8 56.3 35.3 55.6 43.8 50.6 TG (mg/dL) 720 736 722 709 680 840 733 Non-HDL-C (mg/dL) 220 209 216 203 203 215 211 HDL-C (mg/dL) 28 28 31 27 31 25 28 LDL-C (mg/dL) 88 89 92 88 97 80 89 Apo-B (mg/dL) 116 115 120 115 119 106 115 HbA1c ≥6.5% (%) 38.9 44.8 56.3 35.3 50.0 37.5 43.5 ALT (U/L) 29.1 33.9 36.3 36.9 33.0 29.2 32.8 Liver Fat Content (%) (n=24) 16.5 [n=6] 21.3 [n=18] 19.8 [n=3] 18.0 [n=5] 22.4 [n=7] 25.5 [n=3] 20.1[n=24]
Baseline Characteristics: Approximately 50% on Background Therapy Represents Real World Setting Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=16) PGZ 18mg QW (n=17) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Total (n=85) Any background therapy 61% 54% 50% 53% 61% 50% 55% Statins/statin combo 50% 43% 38% 53% 39% 44% 45% Prescription fish oil 11% 15% 6% 12% 22% 19% 14% Fibrates 17% 5% 0 0 17% 0 7% Other 6% 13% 13% 18% 11% 13% 12% Other includes bempedoic acid, ezetimibe alone and ezetimibe as ingredient in combination Background therapy defined as concomitant lipid-modifying therapy Patients may be on > 1 lipid-modifying therapy
Pegozafermin Significantly Reduces Triglycerides across All Dose Groups Primary Endpoint Median Percent Change in Triglycerides from Baseline at Week 8 Q2W QW p value vs placebo for change from baseline based on Wilcoxon Rank-Sum Test Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo QW: Every week; Q2W: Every 2 weeks Q1; Q3: [-64.73; -40.37] Q1; Q3: [-67.60; -39.85] Q1; Q3: [-75.76; -40.03] Q1; Q3: [-62.39; -10.92] Q1; Q3: [-23.22; 7.88]
Q2W QW Q2W QW Median Percent Change in Triglycerides from Baseline at Week 8 Pegozafermin Shows Significant Decrease in Triglycerides on Top of Background Therapy Not On Background Therapy On Background Therapy Full Analysis Set n=6 n=8 n=8 n=6 n=8 n=11 n=8 n=9 n=10 n=8 Background therapy defined as concomitant lipid-modifying therapy Results are consistent with data from patients on background therapy of statins or statin combos, prescription fish oils, and fibrates
Pegozafermin Shows Consistent and Significant Benefit in Triglyceride Reduction across All Key Subgroups Similar trends were observed in subgroup analyses based on other baseline characteristics N=(placebo, PGZ pooled) Placebo PGZ pooled Baseline TG ≥750 mg/dL Yes (n=4,23) -20% -63% No (n=13,42) 0% -52% Type 2 Diabetes Yes (n=10,31) -17% -62% No (n=7,34) -8% -51% Region US (n=13,43) -8% -58% EU (n=4,22) -23% -57% Median Percent Change in Triglycerides from Baseline at Week 8
Full Analysis Set Pegozafermin Shows Significant Decrease in Triglycerides at Different Threshold Levels B. TG Normalization (<150mg/dL, <200mg/dL) Analysis via unstratified Chi-square test comparing the individual PGZ groups vs placebo. * p<0.05; ** p<0.01; *** p<0.001 versus placebo TG Responders defined as patients who achieve TG <500 mg/dL C. TG Reduction ≥50% from baseline A. Responders (< 500 mg/dL) <150 mg/dL <200 mg/dL
p value vs placebo based on MMRM analysis; Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Pegozafermin Demonstrated Clinically Meaningful Improvements in Non-HDL-C – Key Marker of CV Risk Q2W QW Mean Percent Change from Baseline at Week 8 Non-HDL-C 218 Baseline (mg/dL): 216 203 202 215 ‡Behbodikhah J, Metabolites 2021. Non-HDL-C measures the cholesterol in atherogenic particles including LDL-C, IDL-C, and VLDL-C and is considered a better measure of CV risk in hypertriglyceridemia ‡
Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo based on MMRM analysis Pegozafermin Demonstrated Reduction in Absolute Non-HDL-C Absolute Non-HDL-C Reduction is Associated with MACE Improvement Q2W QW Non-HDL-C Mean Absolute Change from Baseline at Week 8 218 Baseline (mg/dL): 216 203 202 215 Mean percent change in HDL-C up to 29% Non-HDL-C reduction of 55 mg/dL is associated with a 25-30% reduction in MI or CV death Figure adapted from: The HPS3/TIMI55–REVEAL Collaborative Group, NEJM 2017; 377: 1217-27 † The HSP3/TIM55-REVEAL Collaboration Group. NEJM, 2017. Non-HDL-C reduction of 55 mg/dL is associated with a 25-30% reduction in MI or CV death†
QW Mean Percent Change from Baseline at Week 8 Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Pegozafermin Demonstrated Clinically Meaningful Improvements in Apo-B – Key Marker of CV Risk Apo-B Apo-B Q2W QW Q2W p value vs placebo based on MMRM analysis Mean Absolute Change from Baseline at Week 8 114 Baseline (mg/dL): 120 115 118 106 114 Baseline (mg/dL): 120 115 118 106 Apo-B is a critical structural protein in atherogenic lipoproteins including LDL-C and is a direct measure of number of atherogenic lipoprotein particles. Apo-B has been proposed as a more accurate indicator of CV risk than LDL-C.1 1Behbodikhah J, Metabolites 2021; Ference B, JAMA 2019.
Q2W QW Mean Relative Reduction in Liver Fat vs Baseline at Week 8 Pegozafermin Demonstrated Significant Reduction in Liver Fat Liver Fat Is an Important Potentiator of CV Risk MRI Analysis Set; p value vs placebo based on ANCOVA analysis *p <0.05 versus placebo n=6 n=3 n=5 n=7 n=2 Post-hoc analysis of patients with follow-up MRI-PDFF ≤21 days from date of last dose in 27mg QW cohort (n=5) demonstrated a 63% mean relative reduction from baseline. High responder rates ≥ 30% Reduction in liver fat: 88% vs 0% in placebo ≥ 50% Reduction in liver fat: 41% vs 0% in placebo Normalized liver fat: 24% vs 0% in placebo Pegozafermin (n=17) and Placebo (n=6) Post-hoc analysis of patients with follow-up MRI-PDFF ≤21 days from date of last dose (n=14) resulted in 29% of patient with normalized liver fat and 100% and 50% of patients with mean relative reductions of ≥30% and ≥50% from baseline, respectively.
Mean Percent Change from Baseline at Week 8 Full Analysis Set Pegozafermin Improved Liver Function Despite Normal Levels at Baseline ALT AST Q2W QW Q2W QW Baseline Mean ALT: 33 U/L (n=85) Baseline Mean AST: 25 U/L (n=85)
Pegozafermin Demonstrated Improvement on HbA1c that May Increase with Longer Treatment Full analysis set; MMRM analysis Absolute Change in HbA1c at Week 8 in ENTRIGUE Pooled Pooled Placebo Placebo Absolute change in HbA1c in 20-week NASH study Study BIO89-100-002; Cohort 7: n=10 at PGZ 27 mg QW HbA1c: Baseline: 7.3%; Week 20: 6.4% Patients with baseline HbA1c ≥ 6.5% were on an average of 2 anti-diabetic medications. *p<0.05; **p<0.01; ***p<0.001. p value for change from baseline based on MMRM analysis Mean absolute change Total Patient Population HbA1c: Mean Baseline 27 mg QW: 7.48%; Week 8: 7.08% Patients with Baseline HbA1c ≥ 6.5% Patients with Baseline HbA1c ≥ 6.5% n=17 n=16 n=6 n=9
Pegozafermin Was Well Tolerated Across Doses Safety profile consistent with prior studies Preferred Term Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=12) PGZ 18mg QW (n=21) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Nausea 0 10% 0% 5% 22% 13% Diarrhea 0 9% 17% 5% 17% 13% Injection site reaction 0 9% 8% 10% 6% 13% Safety Analysis Set; patients reported on as treated basis Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=12) PGZ 18mg QW (n=21) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Serious adverse event (unrelated) 0 1* 0 0 1 0 Treatment emergent discontinuations (related/unrelated) 0 2^/2 0 0 2^/2 0 All AEs were Grade 1 or 2; No Grade 3 or higher TEAEs reported. No tremor or transaminase elevation AEs reported. Low Incidence of Treatment-Related AEs in ≥ 7.5% of Pooled Pegozafermin Group *Unrelated SAE of Grade 2 hypertension; patient withdrew ^Grade 2 abdominal cramps (1) and Grade 2 nausea/vomiting (1)
Pegozafermin – Unique and Differentiated Profile in SHTG Efficacy Significant reduction in triglycerides across all dose groups – up to 63% (27 mg QW) Results consistent in patients with or without background therapy Result consistent across various subgroups (high/low baseline TGs, Type 2 diabetes status) Significant TG normalization rates Significant reduction in liver fat and improvements in liver enzymes and glycemic control markers Potent reduction in atherogenic lipids (Non HDL-C) and apolipoproteins (Apo B) Safety/Tolerability Well tolerated at all doses with low incidence of treatment related adverse events (all Grade 1 or 2)
Proposed Clinical Development Regulatory Seek full approval using endpoint of triglyceride lowering (based on FDA precedent) Propose study duration and study size based on prior precedents for approved drugs Discuss safety database requirements for approval End of Phase 2 meeting planned for 2H22 Clinical Development Conduct single pivotal Phase 3 trial in SHTG Trial initiation expected in 1H23; Topline results expected in 1H25 Consider additional studies to meet safety database requirements per FDA discussions Potential trial(s) in other hypertriglyceridemia patient populations Leverage safety data from NASH studies Phase 3 program is subject to regulatory review/feedback
Proposed Phase 3 SHTG Trial Design SCREENING RANDOMIZATION PLACEBO Pegozafermin^ Pegozafermin MAIN STUDY (12 weeks) EXTENSION PHASE* (12 weeks) PLACEBO Wk 12 Wk 24 PRIMARY ENDPOINT * Extension phase duration expected to be between 12 and 36 weeks TG ≥500 mg/dL Background therapy of statins and/or prescription fish oil and/or fibrates OR not on any background therapy KEY INCLUSION CRITERIA SAMPLE SIZE Approximately 300 patients >90% power for primary endpoint KEY ENDPOINTS Reduction in TG from baseline (primary) Liver fat (MRI-PDFF) Other lipids and metabolic markers Phase 3 program is subject to regulatory review/feedback ^Dose(s) to be decided
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Dr. Deepak L. Bhatt is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Health and Professor of Medicine at Harvard Medical School.
SHTG Represents a Significant Opportunity for Pegozafermin
SHTG Represents a Large Population with High Unmet Needs Co-morbidity Prevalence in SHTG population Fatty Liver Disease (NAFLD) Up to 100% Type 2 diabetes/Prediabetes Up to 70% Dyslipidemia Up to 65% 850k 850k CONTROLLED UNCONTROLLED Prevalence Up to 4 million drug treated ~1.7 MILLION UN-treated ~1.1 MILLION Diagnosed ~2.8 million PEGOZAFERMIN TARGET
In Development Approved Pegozafermin Potential APOC3 Fibrates Prescription Fish Oils Statins Pegozafermin Potential APOC3 Fibrates Vascepa Lovaza Statins Triglyceride reduction ✔✔✔ ✔✔✔ ✔✔ ✔ ✔✔ ✔✔ Liver fat reduction ✔ Worsens liver fat Insulin sensitizing ✔ Cholesterol lowering ✔ (non-HDL-C) ✔ (non-HDL-C) Worsens LDL-C Worsens LDL-C ✔ Apo-B lowering ✔ ✔ ✔ ALT lowering ✔ Transaminase elevations observed Monitor ALT May require ALT monitoring Monitor ALT Pegozafermin has Differentiated Profile Compared with Other TG-Lowering Drugs Sources: Feingold KR. Triglyceride Lowering Drugs. [Updated 2021 Apr 1]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Prescribing information. Corporate presentations. No effect/Not reported Note: All data regarding third-party molecules on this slide are based on third-party studies, which are in different stages of development, and not our own. Conclusions on this slide are company estimates and are not based on head-to-head results. For triglyceride reduction: ✔✔✔ = ≥ 60%, ✔✔ = 31%-59%, ✔ = ≤ 30%
Product profile testing Profile tested: 30% TG reduction plus 1 metabolic benefit (lower than ENTRIGUE data); audience: 150 physicians in 2020 Pegozafermin Profile Represents Substantial Potential in SHTG (Quantitative Market Research Results) Market Share* All Patients PatientS wITH fatty liver 1st line 35% 43% 2nd line 66% 76% *1st line therapeutic options: pegozafermin, APO-C3 inhibitor, a generic prescription fish oil; 2nd line therapeutic options: pegozafermin, APO-C3 inhibitor. Conjoint analysis Profile tested: ENTRIGUE data; audience: 199 physicians in 2022 Analyst consensus estimate of ~$1.0B in peak sales in the US if approved MARKET SHARE: 50% Source: Company estimated based on primary research with ~450 physicians in 2020 and 2022
Corporate Highlights Impacts a broad spectrum of cardio and metabolic endpoints Robust data in 2 indications with a favorable safety and tolerability profile Potential first-to-market FGF21 analog Pegozafermin – potential important new cardio-metabolic drug; balanced effect on multiple key endpoints FGF21 offers greatest promise in this category – addresses multiple facets of the disease Pegozafermin has demonstrated compelling results in clinic Nonalcoholic Steatohepatitis (NASH) – Ph. 2b enrollment completion in 3Q22; data expected 1Q23 $126.1 million cash* as of March 31, 2022; cash runway expected to extend into 2H23 Track record of developing and commercializing successful drugs and business development at other companies Strong cash position with experienced team Highly differentiated based on Phase 2 success across multiple endpoints Significant opportunity given large, under-served market with limited competition Established regulatory pathway allows efficient clinical development Severe Hypertriglyceridemia (SHTG) – Ph. 3 initiation planned in 1H23 * Includes cash and cash equivalents, restricted cash, and short-term available-for-sale securities
Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones SHTG End of Ph. 2 Meeting – 2H22 Phase 3 trial Initiation – 1H23 NASH Complete Enrollment – 3Q22 Topline Data – 1Q23 Plan To Advance Pegozafermin in Clinical Development Phase 2b trial Phase 3 trial - Planning
Appendix
Pegozafermin Is an FGF21 Analog Optimally Engineered to Balance Efficacy and Long Dosing Interval glycoPEG(20kD) C-terminus X Strong and flexible linker (glycoPEGylation technology) Mutations in positions 173 and 176 (glycoPEG attached at position 173) X N-terminus Position 182 FGF21 Proprietary glycoPEGylation technology with site-specific mutations Increases half-life of native FGF21 (< 2 hours) to 55-100 hours based on single ascending dose study Low nanomolar potency against FGF receptors 1c, 2c, 3c, similar to native FGF21 Composition of Matter Patent expiring in 2038 C-terminus N-terminus FGFR FGFR C-terminus β-Klotho β-Klotho Signal transduction Functional response * Composition of matter through 2038
Pegozafermin Significantly Reduces Triglycerides across All Dose Groups Median Change in Absolute Triglyceride Levels from Baseline at Week 8 Q2W QW Full Analysis Set
Median Percent Change in Triglycerides from Baseline at Week 8 Pegozafermin Demonstrated Significant Decrease in Triglycerides Regardless of Baseline TG Level Category Baseline TG ≥750 mg/dL Q2W QW Baseline TG <750 mg/dL Q2W QW Full Analysis Set. n=11 n=12 n=10 n=9 n=4 n=5 n=5 n=6 n=7 n=13
Median Percent Change in Triglycerides from Baseline at Week 8 Pegozafermin Demonstrated Significant Decrease in Triglycerides Regardless of Diabetes Status Patients with T2DM Patients without T2DM Q2W QW Q2W QW Full Analysis Set n=10 n=9 n=6 n=9 n=7 n=7 n=7 n=11 n=7 n=9
Mean Percent Change from Baseline at Week 8 Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Pegozafermin Demonstrated Clinically Meaningful Improvements in HDL-C HDL-C Q2W QW Q2W QW p value vs placebo based on MMRM analysis Mean Absolute Change from Baseline at Week 8 HDL-C 29 Baseline (mg/dL): 31 27 31 25 29 Baseline (mg/dL): 31 27 31 25 LDL-C mean % change from baseline similar between placebo and pegozafermin
Pegozafermin Shows Significant Decrease in Triglycerides on Top of Statins, Prescription Fish Oils and Fibrates Full Analysis Set Background therapy defined as concomitant lipid-modifying therapy Median Percent Change in Triglycerides from Baseline at Week 8 Placebo n=9 PGZ pooled n=28 Placebo n=3 PGZ pooled n=3 Placebo n=2 PGZ pooled n=10
Mean Percent Change from Baseline at Week 8 Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Pegozafermin Demonstrated Clinically Meaningful Improvements in HDL-C and No Change in LDL-C vs. Placebo HDL-C p value vs placebo based on MMRM analysis Mean Percent Change from Baseline at Week 8 LDL-C Existing therapies for SHTG increase LDL-C up to 45%
Pegozafermin 27mg QW Showed Consistent and Robust Effects in Two Indications (SHTG Patients at 8 weeks and NASH Patients at 20 weeks) ` LIVER HEALTH DYSLIPIDEMA INSULIN RESISTANCE ^Mean change from baseline; TG data for SHTG is presented as median SHTG results represents data at 8 weeks from BIO89-100-221 Phase 2 study. NASH results represents cohort 7 data at 20 weeks from Phase 1b/2a BIO89-100-002 study. TG^ HDL-C^ MRI-PDFF^ Non-HDL-C^ Patients with baseline HbA1c ≥ 6.5% Adiponectin^ HbA1c Mean Absolute Reduction HISTOLOGY NASH (cohort 7) NAS >2 NASH Resolution* ≥1 Stage Improvement in Fibrosis** *and no worsening of fibrosis **and no worsening of NASH 74% 32% 26% ALT^ Apo-B^ *Post-hoc analysis of patients with follow-up MRI-PDFF ≤21 days from date of last dose (n=20). Analysis of all patients with follow-up MRI-PDFF (n=23) shows pooled PGZ demonstrated -43% relative reduction from baseline.
Target Product Profile Criteria for a New Therapy (Physician and KOL Research Completed by 89bio Before ENTRIGUE Data Readout) Triglyceride efficacy 30% as add-on therapy (50% is upside case) 30% achieve TG <500 mg (50% is upside case) Cardiometabolic benefits offer added value Liver Fat reduction: 40% reduction from baseline HbA1c: 0.5% to 0.8% reduction in patients with T2DM Lipid changes: Non-HDL-C reduced by 25% LDL and HDL not changed (improvements is upside case) Pegozafermin Profile in ENTRIGUE Significantly Exceeded Target Levels Source: Company estimates based on 2 Advisory Board Meetings with KOLs and Primary Research with 150 Physicians (2020)
KOL Experts & Physicians – Pegozafermin profile is unique and compelling Target patient Patient with uncontrolled TGs despite drug therapy or past episode of acute pancreatitis Patient with history of cardiovascular risk factors Patients with background metabolic syndrome symptoms Ideal profile – reduces TG to <500 mg/dL and reduces liver fat Glycemic control and other lipid benefits are additive Pegozafermin data exceeds threshold for adoption: 30% reduction in triglycerides >50% reduction in triglycerides viewed as “excellent” Metabolic benefits make it a preferred option for patients with Fatty Liver Disease and T2DM KOL Experts & Physicians – Market Dynamics Lack of good treatment options in 2nd and 3rd line setting – highest unmet need Triglyceride management is critical given CV and acute pancreatitis risk; however, often overlooked given limitations of current therapies Extensive Market Research Supports Pegozafermin Promise in SHTG Sources: Company estimates based on Qualitative: 3 Expert Ad Boards, 30 treating physicians and Quantitative: 3 rounds with 450 physicians (cardiologists, endocrinologists, primary care physicians) market research
Payers – Managed Care Directors and PBMs Pegozafermin has potential to gain broad coverage based on approved indication; market is not actively managed Data supportive of premium pricing in 2nd line setting (threshold – 30% reduction in TG) We believe that majority of plans would place pegozafermin on tier with a patient co-pay ≤$60/month Extensive Market Research Supports Pegozafermin Promise in SHTG Sources: Company estimates based on its market research involving 2 rounds with Managed Care Pharmacy or Medical Directors representing >60M lives; PBM Pharmacy or Medical Directors representing with 250M lives
SAFETY / TOLERABILITY FISH OILS FIBRATES Vascepa (EPA) Lovaza (EPA+DHA) Tricor May prolong bleeding time Myopathy, Creatinine increases, DDI Current Therapies Have Had Commercial Success Despite Less than Ideal Profiles TG LDL-C Changes from baseline Vascepa Lovaza Tricor ~$1B (Peak) >~$1B (Peak) ~$580M 2021 Sales revenue * Conclusions on this slide are not based on head-to-head results Lipitor decreases TG by 39% (low dose) and 52% (high dose). Level of sales for hypertriglyceridemia are unknown.